AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / August 17, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that it will give a live streamed update focusing on its project platform NeuroRestore and Alzheimer's disease on September 1 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Fredrik Thor, analyst at Redeye.
Martin Jönsson, CEO at AlzeCure, together with Johan Sandin, CSO, and Pontus Forsell, Head of Discovery & Research, will present the NeuroRestore platform and the clinical development plan for the company's leading drug candidate ACD856. In addition, Professor Maria Eriksdotter, M.D., PhD, at the Karolinska Institute, will give her view on the neurotrophins BDNF / NGF and potential link to and therapeutic role in Alzheimer's disease.
Watch the livestream on September 1 at 09:00 CEST via:
https://www.redeye.se/events/816325/strategy-update-alzecure-pharma-2
More information and registration:
https://www.lyyti.in/Strategy_Update_AlzeCure_Pharma_4394
The presentation will be held in English.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
AlzeCure gives live streamed strategy update on Alzheimer's disease and NeuroRestore on September 1
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/660083/Alzecure-Gives-Live-Streamed-Strategy-Update-on-Alzheimers-Disease-and-NeuroreStore-on-September-1
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata to Participate in Multiple Upcoming Investor Conferences15.5.2025 16:15:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / INNODATA INC. (Nasdaq:INOD), a leading data engineering company, today announced that it will participate in several upcoming investor conferences in May and June 2025. The scheduled conferences include: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025, Minneapolis TD Cowen 53rd Annual Technology, Media & Telecom Conference May 29, 2025, New York Stifel's Eighth Annual Boston Cross Sector Insight Conference June 4, 2025, Boston Maxim Group 2025 Virtual Tech Conference June 5, 2025, Virtual Mizuho Technology Conference 2025 June 10, 2025, New York Jack Abuhoff, CEO, and Aneesh Pendharkar, SVP of Finance and Corporate Development, will be available for one-on-one meetings with investors at each conference. Investors who wish to request a meeting with Innodata at any of these conferences should contact their representative at the sponsoring investment firm. Additionally, Jack Abuhoff will be presenting at the TD Cowen
Loar Announces Pricing of Secondary Public Offering14.5.2025 21:55:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 14, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the pricing of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders at $83.41 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 16, 2025, subject to customary closing conditions. The selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the offering. Moelis & Company, Citigroup and RBC Capital Markets are additionally acting as book runners. Blackstone is acting as co-manager. An automatic shelf regis
Maxon Introduces New Real-Time Rendering and Cinematic Previews Solution for Architects14.5.2025 02:10:00 CEST | Press release
Maxon gives first preview of new solution with partner Vectorworks at AIA Conference on Architecture & Design 2025 BAD HOMBURG, GERMANY / ACCESS Newswire / May 14, 2025 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming and more, is further optimizing its cinematic rendering technology for architectural visualization (ArchViz). For decades, Maxon's technology has empowered top artists to achieve the impossible in both the real world and imaginary-from architecture, construction and product design, to mind-bending visual effects, animation and 3D sculpting. Now, that same level of excellence is being engineered specifically for architects and designers-expanding on the power of Maxon's Cinema 4D and Redshift solutions to meet the demands of real-world, real-time architecture design workflows. Seamlessly integrating with major CAD and BIM tools like Vectorworks, this new platform will allow users t
Loar Announces Launch of Secondary Public Offering13.5.2025 16:26:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the launch of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Such selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the proposed offering. Blackstone is acting as co-manager. An automatic shelf registration statement (including a base prospectus) relating to this offering of common stock was filed by Loar with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and became effec
Detego Global Announces Sponsorship of British Police Rugby Team for 2025 Centenary Tour of South Africa13.5.2025 12:30:00 CEST | Press release
HORSHAM, UNITED KINGDOM / ACCESS Newswire / May 13, 2025 / Following the resounding success of their sponsorship of the England Police Rugby Team's 2024 South African tour, Detego Global, the leading provider of cutting-edge digital forensics and investigative technology, is proud to announce its sponsorship of the British Police Rugby Team's 2025 centenary tour of South Africa, bringing together players from all four nations of England, Ireland, Scotland, and Wales. This new partnership strengthens a shared commitment to community engagement and global cooperation whilst marking an important occasion - the beginning of the British Police Rugby Team's centenary celebrations. Founded in 1925, the British Police Rugby Team has upheld a proud tradition of sporting excellence and service for a century. The 2025 tour of South Africa launches a year of commemorative events and fixtures, starting with two major matches, including one at the world-famous Hollywoodbets Kings Park Stadium in Dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom